Methadone’s ability to inhibit chloride currents in intestinal epithelial cells has been linked to its interference with lubiprostone-mediated activation of ClC-2 channels. This study focused on elucidating the molecular mechanism underlying methadone’s selective inhibition of recombinant human ClC-2 (hClC-2) channels expressed in HEK293EBNA cells, a high-expression system enabling robust electrophysiological characterization. Whole-cell patch-clamp recordings revealed that hClC-2 channels exhibit time-dependent, voltage-activated chloride currents with inward rectification and sensitivity to CdCl₂, confirming functional expression.
Methadone inhibited both control and lubiprostone-stimulated hClC-2 currents in a concentration-dependent manner, with half-maximal inhibitory concentrations (IC₅₀) of 100 nM for baseline currents and 200–230 nM for activated currents. Notably, methadone’s effect was significantly more pronounced when added prior to patching (66.1% inhibition) than after (28.Anti-Mouse CD25 Antibody Immunology/Inflammation 7%), indicating that it may access intracellular sites or modulate channel conformation before membrane sealing. This suggests methadone does not act solely by blocking open channels but potentially alters channel gating or trafficking.
The involvement of protein kinase A (PKA) signaling was further explored using myristoylated PKA inhibitor (mPKI), a specific inhibitor of PKA activity. Forskolin/IBMX-induced activation of hClC-2 currents was abolished in the presence of mPKI, confirming that this pathway relies on PKA-mediated phosphorylation.Encenicline Purity & Documentation However, lubiprostone-stimulated currents remained unaffected by mPKI, indicating that lubiprostone activates hClC-2 through a PKA-independent mechanism. Despite this, methadone still inhibited both forskolin/IBMX- and lubiprostone-activated currents even in the presence of mPKI, demonstrating that methadone’s action is downstream of PKA activation and not dependent on the same signaling cascade.PMID:35105593
In contrast, methadone had no effect on forskolin/IBMX-stimulated chloride currents in hCFTR-expressing HEK293 cells, highlighting the specificity of its action toward ClC-2. These findings suggest that methadone does not broadly impair chloride transport but selectively targets ClC-2 function, likely through direct interaction with the channel protein or modulation of its regulatory environment.
The lack of naloxone reversal and the high IC₅₀ values compared to mu-opioid receptor affinity further support a non-receptor-mediated mechanism. Given that methadone also inhibits other ion channels such as L-type Ca²⁺ channels and hERG K⁺ channels via direct binding, it is plausible that it interacts with structural motifs within the ClC-2 channel, possibly near the voltage sensor or pore region. While direct binding studies are needed, the current data strongly indicate that methadone disrupts ClC-2 function independently of agonist stimulation or classical opioid receptor pathways.
These results provide a mechanistic basis for the clinical observation that lubiprostone fails to alleviate constipation in patients on methadone therapy. By inhibiting ClC-2-mediated chloride secretion, methadone counteracts the intended therapeutic effect of lubiprostone, underscoring the importance of considering pharmacological interactions between opioids and gastrointestinal ion channels in treatment planning.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com